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Background: Vaccination against herpes zoster was introduced in the United Kingdom in 2013 for indi-
viduals aged 70 years, with a phased catch-up campaign for 71–79 year olds. Vaccine introduction has
resulted in a marked fall in incident herpes zoster and in post-herpetic neuralgia (PHN), but formal eval-
uation of vaccine effectiveness is needed.
Methods: In a population-based cohort study of older individuals born between 1933 and 1946, we used
linked UK anonymised primary care health records for the first three years of the vaccination programme
(01/09/2013–31/08/2016) and multivariable Poisson regression to obtain incidence rates and vaccine
effectiveness (VE) against zoster and PHN.
Results: Among 516,547 individuals, 21% were vaccinated. Incidence of zoster was 3.15/1000 person-
years in vaccinees and 8.80/1000 person-years in unvaccinated individuals. After adjustment, VE was
64% (95%CI = 60–68%) against incident zoster and 81% (95%CI = 61–91%) against PHN, with very similar
VE estimates in the routine and catch-up cohorts. VE against zoster was lower in those with a previous
history of zoster: 47% (95%CI = 31–58%) versus 64% (95%CI = 60–68%) in those without previous zoster.
There was evidence of waning VE over time, from 69% (95%CI = 65–74%) in the first year after vaccination
to 45% (95%CI = 29–57%) by the third year.
Conclusion: This first formal assessment of VE in the UK zoster vaccination programme demonstrates
good effectiveness of zoster vaccine, and very good protection against PHN. The findings provide evidence
that VE is similar across the age groups targeted for vaccination in the UK, and on duration of protection
of the vaccine in public health use. The study provides key information for decision-makers about the
future direction of UK zoster vaccination programme, indicating that the live zoster vaccine may be more
cost-effective than estimated previously. It also supports efforts to communicate the benefits of zoster
vaccination to address the declining coverage observed across the UK.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Herpes zoster occurs following reactivation of latent varicella
zoster virus (VZV) infection. It results in a painful unilateral der-
matomal rash and appreciable short- and long-term morbidity,
notably prolonged pain (post-herpetic neuralgia, PHN). Reactiva-
tion of VZV as zoster is prevented by specific cell-mediated immu-
nity, and thus those who are immunosuppressed are at increased
zoster risk [1]. Zoster incidence also rises markedly with age, due
to immunosenescence and loss of specific immunity to VZV, with
rates of 8–12 per 1000 person-years in individuals aged 80+ years
[2,3]. Older individuals are also more likely to develop PHN follow-
ing zoster [4].
In 2006, a live attenuated vaccine against zoster (Zostavax; Zos-
ter Vaccine Live; Merck & Co) was licensed for use and introduced
in the USA for older individuals. The large US pre-licensure trial of
the vaccine in individuals (median age: 69 years) followed up for a
mean of 3.13 years demonstrated vaccine efficacy against incident
zoster of 51%, with 67% efficacy against PHN [5]. Subsequent US
post-licensure studies of older individuals, with maximum
follow-up of 2–5.8 years, have reported estimates of vaccine
effectiveness (VE) against incident zoster [6–11]. In those with
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estimates in the first three years of follow-up VE has varied from
33% to 55% [6,7,9]. Three post-licensure studies also reported VE
against PHN, with estimates of 55% and 59% in the first three years
[6,9] and 61% in a case-control study which included individuals
vaccinated up to 4.8 years before their zoster diagnosis [10].
Zoster vaccination was introduced in the UK in September 2013,
targeted at individuals aged 70 years (the routine cohort) on 1st
September of that year, and those aged 70 years on 1st September
2014 and 1st September 2015 in the second and third year of the
programme [12,13]. There was also a phased introduction of a
catch-up campaign for older individuals, with the vaccine offered
to those aged 79 years on 1st September 2013 (in the first year);
78 and 79 years on 1st September 2014 (second year), and 78 years
on 1st September 2015 (third year). For both the routine and catch-
up cohorts, unvaccinated individuals continued to be eligible for
vaccination until their 80th birthday [12]. As a live vaccine, the
vaccine is contraindicated for individuals with specific immuno-
suppressive conditions or receiving immunosuppressive therapy
as defined in national guidance [12]. The vaccine is offered in gen-
eral practice throughout the year, although practices are encour-
aged to administer it alongside the annual seasonal influenza
vaccination programme. Vaccine uptake in England has declined
over time, from 61.8% (first year) to 54.9% (third year) in the rou-
tine cohort, and from 59.6% to 55.5% in the catch-up cohort [14,15].
We recently showed that general practice consultations for zos-
ter and for PHN in the first three years of the programme decreased
by 35% and 58% respectively in the routine cohorts, and by 33% and
38% in the catch-up cohorts [16]. However, this ecological study
assessed vaccine impact and did not use patient-level data to for-
mally estimate VE. Therefore, in this study we used linked
individual-level electronic health records to estimate effectiveness
of the zoster vaccine in the first three years of the UK programme
against incident zoster and PHN.
2. Methods
2.1. Data sources
We used anonymised data from the Clinical Practice Research
Datalink (CPRD), which comprises the primary care records from
a representative 7% sample of the UK population [17]. Approxi-
mately 58% of the practices have consented to taking part in the
CPRD linkage scheme, and patients’ records from these practices
are linked to hospitalisation data (Hospital Episode Statistics,
HES), and to patient-level deprivation data (Index of Multiple
Deprivation for the postcode of the patient’s residence) [17].
2.2. Study population
We selected individuals who had at least one year’s prior regis-
tration with a CPRD practice on 1st September 2013. For reasons of
confidentiality, CPRD patients’ month and day of birth are not
available to researchers. We therefore chose individuals born in
the years 1933–1946, to ensure that we included those eligible
for vaccination in the routine programme (individuals born
2/9/1942–1/9/1945, aged 68–70 years in September 2013) and
those eligible for the catch-up programme (born 2/9/1933–
01/09/1937, aged 76–79 in September 2013). Inclusion of the
remaining individuals in the study added statistical power for
determining age effects and extra person-time. In addition, includ-
ing unvaccinated individuals who were ineligible (not of eligible
age) for vaccination helped to mitigate potential confounding by
health-seeking behaviour. This is because our unvaccinated group
comprised not only those who were eligible for vaccination but did
not come forward (who may be at different risk of zoster to eligible
individuals who accepted vaccination), but also those who were
similar in age but ineligible for vaccination (who would be less
likely to be at different baseline risk of zoster to vaccinated
individuals).
We excluded from the study population those who had no con-
tact with their practice (a consultation or prescription) or other
evidence of ongoing care (e.g. recording of test results) at any time
from one year prior to 1st September 2013 until the end of the
follow-up, to remove individuals who were inactive in the data-
base. We also excluded those who had received zoster vaccine
before the start of the national vaccination campaign, and those
who at any point during the study period had an immunosuppres-
sive condition or therapy that was a contraindication for zoster
vaccination (Appendix A details how these conditions/therapies
were identified).
2.3. Outcomes
Incident zoster diagnoses were identified using Read codes in
the CPRD data, supplemented in those with linked hospitalisation
data by diagnoses identified using ICD-10 (International Classifica-
tion of Diseases, 10th revision) codes in the primary or secondary
diagnosis fields of a hospitalisation (code lists are in Appendix B).
If zoster codes occurred in both the CPRD and HES data, the earlier
code was taken as the incident date. Individuals with ongoing zos-
ter episodes at the start of the study period were not considered at
risk of zoster for 365 days after their zoster incident date, or (for
individuals with ongoing zoster consultations extending beyond
a year) until 90 days after their last zoster code. Episodes beginning
with a PHN code were also not included in analyses, as we could
not ascertain whether these individuals had past zoster with ongo-
ing PHN rather than an incident zoster episode; these individuals
also started follow-up at the end of the episode.
We defined PHN as pain persisting 3 months after the zoster
diagnosis [5]. Although there are specific Read and ICD-10 PHN
codes, general practitioners often do not use them, instead record-
ing consultations for pain or prescribed pain medications. We
therefore used an update of our PHN algorithm, based on a vali-
dated algorithm developed for US administrative health data
[18,19]. Briefly, we looked in the 90–365 days after the zoster diag-
nosis for evidence of: PHN codes; combinations of zoster codes,
neuralgia codes and medications used to treat PHN; and referrals
to pain clinics (full definitions are in Appendix C). As anticonvul-
sant drugs and codes for neuropathic pain/neuralgia comprised
part of our PHN algorithm, we excluded from the PHN analysis
patients with a history of epilepsy, other specific conditions that
cause neuropathic pain, or trigeminal neuralgia. We also restricted
patients to those with at least 365 days follow-up after a zoster
diagnosis (or, for those who did not develop zoster, at least
365 days follow-up in the study period) to enable full assessment
of PHN.
2.4. Vaccination status
This was determined from patients’ immunisation, clinical,
therapy and referral files in CPRD. Those with conflicting vaccina-
tion status on the same day (for example records indicating that
the vaccine was both refused and given) were dropped from our
study. Patients were considered fully vaccinated 42 days after the
vaccine was given.
2.5. Covariates
A priori confounders of the relationship between vaccination
status and the outcomes of interest included age, study year and
calendar month. Further potential confounders included sex,
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ethnicity, deprivation status, geographic region, previous history of
zoster, and uptake of seasonal influenza vaccination in the previ-
ous year (as a marker of propensity to consult, and because zoster
vaccine was offered alongside influenza vaccine). We also consid-
ered co-morbidities that are risk factors for zoster, namely
rheumatoid arthritis, systemic lupus erythematosus, inflammatory
bowel disease, chronic kidney disease, chronic obstructive pul-
monary disease, asthma and diabetes mellitus [20]. These condi-
tions were identified using the Read code lists from our previous
zoster study, with individuals considered to have the condition if
they had a diagnostic code at any time before the start of the study
[20]. Age was also grouped to capture the routine (born 1940–
1946) and catch-up (born 1933–1939) cohorts.
2.6. Statistical methods
Start of follow up was the later of 1st September 2013 (the date
of zoster vaccination introduction) and the end of any previous
zoster episode that occurred prior to September 2013. End of fol-
low up for the zoster incidence analysis was the earliest of the date
the patient left the practice or died, the date the data were last col-
lected from the practice, the date of the first zoster episode, and
31st August 2016. For PHN analyses, we only considered zoster
episodes that started on or before 31st Aug 2015, to allow full
assessment of PHN in the year after the zoster diagnosis. The inci-
dent zoster date was used as the date of incident PHN, thus assess-
ing VE against zoster that resulted in PHN.
Vaccine effectiveness against both zoster and PHN was assessed
using multivariable Poisson regression with an offset for person-
time to obtain adjusted incidence rate ratios (IRR). Effectiveness
was calculated as (1IRR) ⁄ 100. The IRRs were adjusted for the a
priori confounders year of age (modelled first as a linear and then
as a quadratic effect), year of study and calendar month; other
potential confounders were retained in the model if they changed
the IRR by 5%. We added interaction terms to the models to
investigate whether VE varied by sex, age (routine vs catch-up
cohort), or between those with and without a history of zoster.
Effectiveness was also calculated by time since vaccination, to
examine waning of protection.
All analyses were carried out using Stata MP 14.
2.7. Ethics approval
Approval was received from the Independent Scientific Advi-
sory Committee of the Medicines and Healthcare Products Regula-
tory Agency (ISAC number: 13.138RA) and the Ethics Committee of
the London School of Hygiene & Tropical Medicine (Reference
number: 14643).
3. Results
Among 516,547 patients born between 1933 and 1946 and
active in CPRD on 1st September 2013, 487,901 individuals with
1,059,179 person-years of follow up (excluding the 42 days of
person-time after vaccination) were eligible for inclusion in the
analyses of VE against incident zoster (Fig. 1). Of these, 380,147
individuals with 585,540 person-years of follow up were included
in analyses of effectiveness against PHN. The characteristics of the
study population are summarised in Table 1. Vaccinated individu-
als in the zoster incidence analyses were followed up for a median
of 1.42 person-years (range: 0.003–2.9), and unvaccinated individ-
uals were followed up for a median of 1.99 person-years (range:
0.003–3.0).
A total of 103,336 individuals (21% of the study population,
15.2% of person-time) were vaccinated. During the study period,
435 vaccinated individuals developed zoster >42 days after vacci-
nation, compared to 8006 unvaccinated individuals, resulting in
zoster incidences of 3.15/1000 person-years and 8.80/1000
person-years respectively (Table 2). After adjusting for age, month
and year of the study, overall VE against incident zoster was 64%
(95%CI = 60–68%). Further adjustment by sex, geographic region,
comorbidities, previous history of zoster and previous receipt of
influenza vaccination, and (in complete case analyses) ethnicity
and IMD did not change the effectiveness estimate (data not
shown). Adding age as a quadratic variable made no material dif-
ference to the results. As 31% of individuals were missing informa-
tion on ethnicity, we repeated analyses restricted to those of White
ethnicity; effectiveness was identical to that found for the entire
cohort (VE = 64%, 95%CI = 60–69%).
There was no evidence that VE differed in the routine and catch-
up cohorts (pinteraction = 0.58), and only weak evidence that VE was
lower among women (VE = 60% (95%CI = 55–64%) versus VE = 66%
(95%CI = 60–71%) among men, pinteraction=0.08, Table 3). In contrast,
VE was lower among those with a history of zoster (VE = 47%, 95%
CI = 31–58% versus VE = 64%, 95%CI = 60–68% among those with no
history of zoster, pinteraction = 0.009, Table 3). Stratification by time
since vaccination showed evidence of waning, with VE decreasing
from 69% (95%CI = 65–74%) in the first year after vaccination to
45% (95%CI = 29–57%) in the third year (pinteraction < 0.001, Table 3).
This waning was seen in both age cohorts, with VE in the routine
cohort falling from 71% in the first post-vaccination year to 52%
by the third year, and VE in the catch-up cohort falling from 69%
to 38% (Table 3).
Eight cases of PHN occurred in vaccinated individuals >42 days
after vaccination and 371 cases occurred in unvaccinated individ-
uals, After adjusting for age, month and year of the study, VE
against PHN was 81% (95%CI = 61–91%, Table 2). As with the zoster
incidence analyses, effectiveness against PHN was similar in the
routine and catch-up cohorts (routine: VE = 84%, 95%CI = 50–95%;
catch-up: VE = 79%, 95%CI = 48–92%). There was no statistical evi-
dence of heterogeneity in VE by sex, history of zoster, or time since
vaccination (pinteraction > 0.4 for all), but analyses were limited by
the small number of PHN cases among vaccinated individuals.
4. Discussion
This first formal assessment of VE in the UK zoster vaccination
programme provides important evidence of the effectiveness of
zoster vaccine in public health use, demonstrating 62% effective-
ness against incident zoster and higher effectiveness (81%) against
its most common severe complication, PHN. We found very similar
VE in the two age groups targeted for vaccination in the UK, but
lower effectiveness (47%) among those with a previous history of
zoster. Effectiveness decreased within the first three years after
vaccination, from 69% in the first year to 45% by three years.
Our findings add to our recent ecological study of the impact of
vaccine introduction in the UK, which showed marked reductions
in both zoster incidence and PHN in the first three years of the vac-
cination programme [16]. Our current study’s VE estimates are
somewhat higher than those from the US pre-licensure trial(which
included individuals aged 60 years at enrolment, with >6.5%
older than 80 years): 62% vs 51% against incident zoster and 81%
vs 67% for PHN [5]. However, the cases in the current study all
sought care for their zoster, whereas the trial involved active fol-
low up of all participants. We therefore may not have captured
the mildest cases of zoster, and our findings are consistent with
reports that the vaccine may afford higher protection against more
severe zoster [5,9]. Furthermore, the confidence intervals for the
two PHN VE estimates overlapped, and the differences could reflect
random error. Our finding that VE was near-identical in the routine
J.L. Walker et al. / Vaccine xxx (2018) xxx–xxx 3
Please cite this article in press as: Walker JL et al. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine (2018),
https://doi.org/10.1016/j.vaccine.2018.02.021
and catch-up cohorts is also different to the trial results, but con-
sistent with findings from two US post-licensure studies that
reported very similar VE in those aged 70–74 years and 75–79
years [7,9]. Two recent US studies that stratified VE estimates by
both age and time since vaccination have also shown similar wan-
ing of VE in the first, second and third years, with VE of 64.5%,
45.2% and 36.8% among individuals aged 70–79 years, and 67%,
47% and 34% among individuals aged 70 years [8,11]. The lower
VE we identified among those with a history of zoster is, to the best
of our knowledge, a novel finding that warrants further investiga-
tion. Those who experience a second zoster event may have less
well-functioning immune systems (among whom the vaccine
may not be as effective). However, we had no information on the
timing of past zoster, which could explain our results if there
was differential uptake among those with recent and less recent
zoster – for example if those who had more recent zoster (who
might be well protected against subsequent VZV reactivation
because of boosted immunity) were less likely to come forward
for vaccination compared to those who had zoster less recently
(who would be less well protected, due to waning immunity).
Our study has several strengths. This was a large, population-
based study using a representative sample of the UK population
in a general practice setting; as the UK zoster vaccine programme
is delivered via general practice, this maximised capture of zoster
vaccination status. Linkage to hospitalisation records enabled bet-
ter ascertainment of zoster, including cases that presented directly
to hospital that might be incompletely recorded in the general
practice data. Our detailed algorithm for identifying PHN allowed
identification of cases that would have been missed if we had
restricted the PHN case definition to specific PHN medical codes.
Similarly, we used extensive methods to identify and exclude indi-
viduals with immunosuppression who are ineligible to receive the
live zoster vaccine. As these individuals should almost all be
unvaccinated and are at appreciably higher risk of zoster, their
exclusion from analyses helped to avoid underestimation of VE.
Despite not having patients’ exact date of birth (and thus not pin-
pointing exactly those eligible for vaccination), inclusion of a range
of birth cohorts may have helped to minimise confounding result-
ing from health-seeking behaviour.
Some study limitations also need consideration. Zoster is usu-
ally diagnosed clinically, without virological confirmation. Thus,
misclassification of the outcomemay have occurred. However, zos-
ter has a very characteristic clinical presentation and the diagnosis
is usually straightforward. A Dutch validation study of zoster diag-
noses made in primary care reported that nearly 91% of individuals
with clinical zoster had elevated VZV antibodies (suggesting recent
reactivation of VZV), demonstrating a high positive predictive
value for the clinical diagnosis by general practitioners [21].
Despite our extensive range of case definitions used to identify
PHN, we may have not ascertained some cases, due to the variety
of ways in which general practitioners can record these diagnoses.
Furthermore, some individuals with persistent pain after zoster
may have used over-the-counter pain medications and not con-
sulted their GP; as all these individuals sought care for their initial
zoster, it is likely that any misclassification would be non-
differential with respect to vaccination status, resulting in possible
under-estimation of VE against PHN. Despite the large size of our
data, there were few PHN events among vaccinated individuals,
decreasing the precision of some estimates and preventing investi-
gation of effect modification. A further potential limitation of the
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Fig. 1. Selection of individuals for vaccine effectiveness analyses.
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PHN analysis was the requirement that individuals have at least
one year follow-up after zoster (for those who developed zoster)
or one year active follow-up (for those who did not develop zoster),
to allow sufficient time to capture PHN. This additional inclusion
criterion may have limited the generalisability of our VE estimate
to those who did not die soon after developing zoster. However,
as less than 2% of individuals (both those with zoster and those
without) who were excluded from the PHN analyses were
excluded because they had died, this is unlikely to have affected
the generalisability of our findings to any great extent. We consid-
ered many potential confounders including a range of comorbidi-
ties associated with increased zoster risk, but residual
confounding could have occurred, for example if more frail individ-
uals (with less well-functioning immune systems) were less likely
to receive zoster vaccination. Information on participants’ ethnicity
was incomplete, but the results of our sensitivity analysis
restricted to individuals of White ethnicity suggests that this did
not affect results.
These new VE estimates, including the evidence of waning over
time, contribute key information for decision-makers about the UK
zoster vaccination programme. Our finding of similar VE among
younger and older individuals is important, given the choice of
age group currently offered vaccination (those aged 70 and
78/79 years). Reviewing optimal vaccine strategies also includes
consideration of the relative merits of the current live vaccine with
the new sub-unit zoster vaccine, which (unlike the live vaccine)
can be administered to those with immunosuppression, a group
at particularly high risk of zoster [22]. Notably, our VE estimates
Table 1
Person-years by vaccination status and study population characteristics for (a) zoster incidence analyses and (b) post-herpetic neuralgia (PHN) analyses.
Characteristic (a) Zoster incidence analyses person years:a (b) PHN analyses person years:a
Vaccinatedb (137,968py) Unvaccinatedb (909,474 py) Vaccinatedc (52,861py) Unvaccinatedc (526,055py)
Sex
Male 64,925 424,381 24,472 242,812
Female 73,044 485,093 28,389 283,243
Time since vaccination
Unvaccinated – 909,474 – 526,055
Up to 1 year since vaccination 75,707 – 39,172 –
1 to <2 years since vaccination 47,954 – 13,689 –
2–3 years since vaccination 14,307 – 04 –
Ethnicity
White 81,378 527,387 30,286 297,068
South Asian 1275 11,318 436 5586
Black 615 6751 240 3428
Other 580 5617 212 3093
Mixed 149 1277 55 672
Not stated 6480 46,281 2,512 26,740
Missing 47,492 310,843 19,120 189,467
Cohort
Routine (born 1940–1946) 77,319 540,007 30,631 313,448
Catch-up (born 1933–1939) 60,649 369,467 22,230 212,606
IMD status
1 19,903 127,120 7475 71,164
2 16,305 115,308 5849 62,392
3 14,603 104,251 5336 57,082
4 10,813 81,814 3879 44,049
5 6772 54,584 2463 28,871
Missing 69,573 426,397 27,859 262,497
History of zoster
History 14,784 88,358 5753 51,730
No history 123,185 821,116 47,108 474,325
Influenza vaccination
Given the previous year 127,358 653,297 48,569 379,111
Not given the previous year 10,610 256,177 4292 146,943
a Excludes the person-time in the 6 weeks after vaccination.
b Median follow-up time: vaccinated = 1.42 person-years (range: 0.003–2.9); unvaccinated = 1.99 person-years (range: 0.003–3.0).
c Median follow up time: vaccinated = 0.80 person-years (range: 0.003–1.88); unvaccinated = 1.69 person-years (range 0.003–2.0).
d Only includes follow-up of zoster to the end of year 2, to allow detection of PHN in the year after incident zoster.
Table 2
Vaccine effectiveness (VE) against (a) incident zoster and (b) post-herpetic neuralgia (PHN).
Vaccination status Cases (n) Person-yearsa Rate/1000py Adjusted IRRb (95% CI) VE (95% CI)
(a) Outcome: incident zoster
Unvaccinated 8006 909,474 8.80 1.00 1.00
Vaccinated 435 137,968 3.15 0.38 (0.34, 0.42) 62% (58%, 66%)
(b) Outcome: PHN
Unvaccinated 371 526,055 0.70 1.00
Vaccinated 8 52,861 0.15 0.19 (0.09, 0.39) 81% (61%, 91%)
a Excludes person-time in the 42 days after vaccination.
b Incidence rate ratio, adjusted for age in years, month and year of study.
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indicate that the live zoster vaccine programme might be more
cost-effective for the NHS than estimated in the 2009 study which
modelled VE based on the results from the US pre-licensure trial
[23]. Ongoing monitoring of zoster VE over time will be important
to obtain robust estimates of waning effectiveness over a longer
period. Our findings should also help to demonstrate to healthcare
workers and the older population that the vaccine is effective, par-
ticularly against long-term pain following zoster. This may help to
increase vaccination coverage among the older UK population and
reverse the recent decline in vaccine uptake.
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